The CNS Market Outlook to 2011

Publication Date	November 2006
Publisher	Business Insights
Product Type	Report
Pages	216
ISBN Number	not applicable
Product Code	RBI00126

Price

£1,495.00
approximately: $2,793 | €1,896

PDF

PRINT £1,545 ($2,887 | €1,960)

Order above formats by FAX

Summary

Psychiatric and neurological disorders constitute as much as 35% of the disease burden in the seven major pharmaceutical markets, representing continuing opportunities for pharma companies in the CNS market. However, the increasing presence of generic products coupled with low levels of innovative launches has resulted in a slowdown in market growth and considerable unmet need across the spectrum of CNS disorders.

The CNS Market Outlook to 2011 provides comprehensive epidemiological analysis of the major CNS indications and key factors impacting market and competitive dynamics. This report will enable you to identify growth brands, key drug classes and leading companies through to 2011, pin-pointing market trends that will influence future sales of treatments within the CNS market.

Evaluate changes in the competitive positions of the leading companies in the CNS market and ensure your R&D pipeline is aligned with future market opportunity to maximize commercial success.

Key findings of the report...

Sales of the leading nine companies in the CNS market were $51,884m in 2005, 0.8% down on year previous sales reported at $52,299m. The performance of the leading nine companies underperformed that of the total market which recorded a growth rate of 5.5% for 2005.
Alzheimer's disease is forecast to be the primary growth driver in the CNS market over the forecast period, with a CAGR estimated at 10.3% for 2005-11. This growth is attributed to the arrival of new products and the implementation of successful strategies by major pharmaceutical companies to protect existing revenue streams.
Of the most promising compounds identified in this report, five are replacement compounds for blockbusters that have or are forecast to lose patent protection over the forecast period to 2011. Such products include J&J's paliperidone, Lilly's Symbyax, Pfizer's Lyrica, and Wyeth's DVS-233.
Epilepsy is forecast to become a fiercely competitive indication over the forecast period with heavy genericization setting in. Major companies are looking at different strategies in addition to new indications to protect sales of their products from generics.

Key questions answered in this report

What will be the major growth indications in the CNS market over the period 2006-11?
Which companies were the winners and losers in the CNS market in 2005?
How have recent launches from Pfizer, AstraZeneca, Forest and Bristol-Myers Squibb performed?
How have the recent patent expirations on key products affected the dynamics of the CNS market?
How significant is the threat of generic competition to the overall performance of the migraine, schizophrenia and epilepsy markets?
Which pipeline products feature highest growth potential and why?
What will the competitive landscapes of the major sub-indications of depression, schizophrenia, Alzheimer's disease (AD), Parkinson's disease (PD), and migraine look like in 2011?

Top five reasons to order your copy today

Access the latest in research with the report's coverage of the 6 largest indications in the CNS market, the 7 largest geographic pharmaceutical markets and the 9 largest companies active in the CNS market today.
Discover which indications have the greatest potential to provide franchise growth and how major players are attempting to utilize these opportunities.
Evaluate how the market share of leading companies, such as Johnson & Johnson, Pfizer, GlaxoSmithKline and Lilly, will change over the next 6 years and assess your company's competitive position within the market.
Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in the CNS marketplace.
Gain access to the CNS pipelines of the 9 leading players to understand which companies will have a presence in key indications over the next 6 years.

Content

Executive Summary
- Patient potential
- Global market analysis
- Analysis of potential future CNS blockbusters
- Leading players in the CNS market
Chapter 1 Patient potential
- Summary
- Introduction
- Alzheimer's disease
- Background
- Diagnosis and treatment
- Prevalence
- Forecast prevalence of Alzheimer's disease
- Depression
- Background
- Diagnosis and treatment
- Prevalence
- Forecast prevalence of depression/anxiety
- Epilepsy
- Background
- Diagnosis and treatment
- Prevalence
- Forecast prevalence of epilepsy
- Migraine
- Background
- Diagnosis and treatment
- Prevalence
- Forecast prevalence of migraine
- Parkinson's disease
- Background
- Diagnosis and treatment
- Prevalence
- Forecast prevalence of Parkinson's disease
- Schizophrenia
- Background
- Diagnosis and treatment
- Prevalence
- Forecast prevalence of schizophrenia
Chapter 2 Global market analysis
- Summary
- Introduction
- Alzheimer's disease
- Introduction
- Analysis of the leading Alzheimer's disease treatments
- Market analysis by drug class
- Cholinesterase inhibitors
- NMDA antagonists
- Depression
- Introduction
- Analysis of the leading anti-depressant treatments
- Market analysis by drug class
- Selective serotonin reuptake inhibitors
- Serotonin norepinephrine reuptake inhibitors
- Others
- Epilepsy
- Introduction
- Analysis of the leading epilepsy treatments
- Market analysis by drug class
- Traditional anti-convulsants
- Second generation anti-convulsants
- Parkinson's disease
- Introduction
- Analysis of the leading Parkinson's disease treatments
- Market analysis
- COMT inhibitors
- Dopaminergics
- Dopamine agonists
- Migraine
- Introduction
- Analysis of the leading migraine treatments
- Market analysis by drug class
- Triptans
- Schizophrenia
- Introduction
- Analysis of the leading anti-psychotic treatments
- Market analysis by drug class
- Typical anti-psychotics
- Atypical anti-psychotics
- CNS market forecasts
Chapter 3 Analysis of potential future CNS blockbusters
- Summary
- Introduction
- Drug profiles
- Phase II pipeline drugs
- E 2007
- Phase III pipeline drugs
- Xenox (xaliproden)
- Lacosamide
- Asenapine
- Saredutant
- Alzhemed (tramipostate)
- Drugs in registration
- DVS-233 (desvenlafaxine)
- Paliperidone
- Inovelon (rufinamide)
- Recently marketed drugs
- Lyrica (pregabalin)
- Symbyax (olanzapine/fluoxetine)
- Agilect/Azilect (rasagiline)
Chapter 4 Leading players in the CNS market
- Summary
- Introduction
- Global market shares
- Johnson & Johnson
- Marketed products
- R&D compounds
- CNS portfolio sales forecasts
- Pfizer
- Marketed products
- R&D compounds
- CNS portfolio sales forecasts
- GSK
- Marketed products
- R&D compounds
- CNS portfolio sales forecasts
- Lilly
- Marketed products
- R&D compounds
- CNS portfolio sales forecasts
- Sanofi-Aventis
- Marketed products
- R&D compounds
- CNS portfolio sales forecasts
- AstraZeneca
- Marketed products
- R&D compounds
- CNS portfolio sales forecasts
- Wyeth
- Marketed products
- R&D compounds
- CNS portfolio sales forecasts
- Novartis
- Marketed products
- R&D compounds
- CNS portfolio sales forecasts
- Forest Labs
- Marketed products
- R&D compounds
- CNS portfolio sales forecasts
Chapter 5 Appendix
- Glossary
- Index
List of Figures
- Figure 2.1: Competitive dynamics of drug classes in the Alzheimer's disease market, 2005
- Figure 2.2: Competitive dynamics of leading brands in the Alzheimer's disease market, 2005
- Figure 2.3: Competitive dynamics of drug classes in the depression market, 2005
- Figure 2.4: Competitive dynamics of leading brands in the depression market, 2005
- Figure 2.5: Competitive dynamics of drug classes in the epilepsy market, 2005
- Figure 2.6: Competitive dynamics of leading brands in the epilepsy market, 200405
- Figure 2.7: Competitive dynamics of leading brands in the Parkinson's disease market, 2005
- Figure 2.8: Competitive dynamics of leading brands in the migraine market, 2005
- Figure 2.9: Competitive dynamics of drug classes in the schizophrenia market, 200405
- Figure 2.10: Competitive dynamics of leading brands in the schizophrenia market, 200405
- Figure 3.11: Leading drugs in development, 2005
- Figure 4.12: Key players in the global CNS market, 2001 and 2005
List of Tables
- Table 1.1: Prevalence of Alzheimer's disease in the seven major markets, 2005
- Table 1.2: Forecast prevalence of Alzheimer's disease in the seven major markets, 2006-11
- Table 1.3: Prevalence of MDD/anxiety in the seven major markets, 2005
- Table 1.4: Forecast prevalence of depression/anxiety in the seven major markets, 2006-11
- Table 1.5: Prevalence of epilepsy in the seven major markets, 2005
- Table 1.6: Forecast prevalence of epilepsy in the seven major markets, 2006-11
- Table 1.7: Prevalence of migraine in the seven major markets, 2005
- Table 1.8: Forecast prevalence of migraine in the 7 major markets, 2006-11
- Table 1.9: Prevalence of Parkinson's disease in the seven major markets, 2005
- Table 1.10: Forecast prevalence of Parkinson's disease in the seven major markets, 2006-11
- Table 1.11: Prevalence of schizophrenia in the seven major markets, 2005
- Table 1.12: Forecast prevalence of schizophrenia in the seven major markets, 2006-11
- Table 2.13: Breakdown of the global Alzheimer's disease market by drug class, 2001-05
- Table 2.14: Breakdown of the global Alzheimer's disease market by leading brands, 2004-05
- Table 2.15: Breakdown of the global depression market by drug class, 2001-05
- Table 2.16: Breakdown of the global depression market by leading brands, 2004-05
- Table 2.17: Breakdown of the global epilepsy market by drug class, 2001-05
- Table 2.18: Breakdown of the global epilepsy market by leading brands, 2004-05
- Table 2.19: The global Parkinson's disease market, 2004-05
- Table 2.20: Breakdown of the global Parkinson's disease market by leading brands, 2004-05
- Table 2.21: Breakdown of the global migraine market by drug class, 2001-05
- Table 2.22: Breakdown of the global migraine market by leading brands, 2004-05
- Table 2.23: Breakdown of the global anti-psychotics market by drug class, 2001-05
- Table 2.24: Breakdown of the global anti-psychotics market by leading brands, 200405
- Table 2.25: Forecast global sales for major CNS indications, 2005-11
- Table 4.26: Key players in the global CNS market, 2005
- Table 4.27: J&J's marketed CNS portfolio, 2005
- Table 4.28: J&J's CNS R&D pipeline, 2006
- Table 4.29: Forecast sales for J&J's CNS portfolio, 200511
- Table 4.30: Pfizer's marketed CNS portfolio, 2005
- Table 4.31: Pfizer's CNS R&D pipeline, 2006
- Table 4.32: Forecast sales for Pfizer's CNS portfolio, 200511
- Table 4.33: GSK's marketed CNS portfolio, 2005
- Table 4.34: GSK's CNS R&D pipeline, 2006
- Table 4.35: Forecast sales for GSK's CNS portfolio, 200511
- Table 4.36: Lilly's marketed CNS portfolio, 2005
- Table 4.37: Lilly's CNS R&D pipeline, 2006
- Table 4.38: Forecast sales for Lilly's CNS portfolio, 200511
- Table 4.39: Sanofi-Aventis' marketed CNS portfolio, 2005
- Table 4.40: Sanofi-Aventis' CNS R&D pipeline, 2006
- Table 4.41: Forecast sales for Sanofi-Aventis' CNS portfolio, 200511
- Table 4.42: AstraZeneca's marketed CNS portfolio, 2005
- Table 4.43: AstraZeneca's CNS R&D pipeline, 2006
- Table 4.44: Forecast sales for AstraZeneca's CNS portfolio, 200511
- Table 4.45: Wyeth's marketed CNS portfolio, 2005
- Table 4.46: Wyeth's CNS R&D pipeline, 2006
- Table 4.47: Forecast sales for Wyeth's CNS portfolio, 200511
- Table 4.48: Novartis' marketed CNS portfolio, 2005
- Table 4.49: Novartis' CNS R&D pipeline, 2006
- Table 4.50: Forecast sales for Novartis' CNS portfolio, 200511
- Table 4.51: Forest's marketed CNS portfolio, 2005
- Table 4.52: Forest's CNS R&D pipeline, 2006
- Table 4.53: Forecast sales for Forest's CNS portfolio, 200511